These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 20691610

  • 1. Effect of transjugular intrahepatic portosystemic shunt placement on renal function: a 7-year, single-center experience.
    Anderson CL, Saad WE, Kalagher SD, Caldwell S, Sabri S, Turba UC, Matsumoto AH, Angle JF.
    J Vasc Interv Radiol; 2010 Sep; 21(9):1370-6. PubMed ID: 20691610
    [Abstract] [Full Text] [Related]

  • 2. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, Valente U.
    Hepatogastroenterology; 2003 Sep; 50(54):1753-5. PubMed ID: 14696397
    [Abstract] [Full Text] [Related]

  • 3. Transjugular intrahepatic portosystemic shunts in hemodialysis-dependent patients and patients with advanced renal insufficiency: safety, caution, and encephalopathy.
    Haskal ZJ, Radhakrishnan J.
    J Vasc Interv Radiol; 2008 Apr; 19(4):516-20. PubMed ID: 18375295
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Transplantation: impact of pretransplant renal insufficiency.
    Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, Bloom RD, Reddy KR.
    Liver Transpl; 2008 May; 14(5):665-71. PubMed ID: 18433034
    [Abstract] [Full Text] [Related]

  • 6. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J.
    Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
    [Abstract] [Full Text] [Related]

  • 7. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis.
    Appenrodt B, Zielinski J, Brensing KA, Heller J, Sauerbruch T, Schepke M.
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1428-32. PubMed ID: 19794309
    [Abstract] [Full Text] [Related]

  • 8. Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.
    Saad WE, Darwish WM, Davies MG, Waldman DL.
    J Vasc Interv Radiol; 2010 Feb; 21(2):218-23. PubMed ID: 20123207
    [Abstract] [Full Text] [Related]

  • 9. Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt.
    Russo MW, Jacques PF, Mauro M, Odell P, Brown RS.
    Liver Transpl; 2002 Mar; 8(3):271-7. PubMed ID: 11910573
    [Abstract] [Full Text] [Related]

  • 10. Transplantation: impact of pretransplant renal insufficiency.
    Pham PT, Wilkinson AH.
    Liver Transpl; 2008 May; 14(5):592-5. PubMed ID: 18433066
    [No Abstract] [Full Text] [Related]

  • 11. Factors predicting survival after transjugular intrahepatic portosystemic shunt creation: 15 years' experience from a single tertiary medical center.
    Pan JJ, Chen C, Caridi JG, Geller B, Firpi R, Machicao VI, Hawkins IF, Soldevila-Pico C, Nelson DR, Morelli G.
    J Vasc Interv Radiol; 2008 Nov; 19(11):1576-81. PubMed ID: 18789725
    [Abstract] [Full Text] [Related]

  • 12. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality.
    Russo MW, Sood A, Jacobson IM, Brown RS.
    Am J Gastroenterol; 2003 Nov; 98(11):2521-7. PubMed ID: 14638358
    [Abstract] [Full Text] [Related]

  • 13. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F, Pantea L, Sniderman K.
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [Abstract] [Full Text] [Related]

  • 14. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk.
    Parvinian A, Shah KD, Couture PM, Minocha J, Knuttinen MG, Bui JT, Gaba RC.
    J Vasc Interv Radiol; 2013 Jul; 24(7):941-6. PubMed ID: 23707226
    [Abstract] [Full Text] [Related]

  • 15. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
    Deschênes M, Dufresne MP, Bui B, Fenyves D, Spahr L, Roy L, Lafortune M, Pomier-Layrargues G.
    Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
    [Abstract] [Full Text] [Related]

  • 16. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.
    Rössle M, Ochs A, Gülberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL.
    N Engl J Med; 2000 Jun 08; 342(23):1701-7. PubMed ID: 10841872
    [Abstract] [Full Text] [Related]

  • 17. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
    Arroyo V, Terra C, Ginès P.
    J Hepatol; 2007 May 08; 46(5):935-46. PubMed ID: 17391801
    [No Abstract] [Full Text] [Related]

  • 18. Prognostic value of hepatocyte proliferative activity after transjugular intrahepatic portosystemic shunt.
    Delhaye M, Le Moine O, Degraef C, Devière J, Galand P.
    Am J Gastroenterol; 2001 Jun 08; 96(6):1866-71. PubMed ID: 11419841
    [Abstract] [Full Text] [Related]

  • 19. Transjugular intrahepatic portosystemic shunts: experience in the oncology setting.
    Wallace MJ, Madoff DC, Ahrar K, Warneke CL.
    Cancer; 2004 Jul 15; 101(2):337-45. PubMed ID: 15241832
    [Abstract] [Full Text] [Related]

  • 20. [Transjugular intrahepatic portosystemic shunt (TIPS). Therapeutic alternative in refractory ascites and varicose bleeding].
    Olin M, Ivancev K, Verbaan H.
    Lakartidningen; 2004 Jul 15; 105(37):2490-4. PubMed ID: 19006865
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.